Loading...
•
Dec 31, 2025
Palatin Technologies Q2 2026 Earnings Report
Palatin Technologies reported second quarter fiscal year 2026 results with increased operating expenses driven by obesity program development and a net loss for the quarter.
Key Takeaways
Palatin reported collaboration and license revenue of 116036 for Q2 fiscal 2026 and a net loss of 7263861, reflecting higher R&D and G&A expenses tied to its MC4R obesity programs. The company strengthened its cash position to 14476162 following its November public offering.
Collaboration and license revenue was 116036 for the quarter.
Net loss totaled 7263861, or 2.86 per share.
Total operating expenses increased to 7444584 driven by obesity program development.
Cash and cash equivalents increased to 14476162 as of December 31, 2025.
Revenue by Segment
Forward Guidance
Palatin plans to advance its MC4R-based obesity programs into clinical development in 2026 while leveraging partnerships and its strengthened balance sheet to support operations.
Positive Outlook
- PL7737 oral MC4R agonist on track for IND submission and Phase 1 initiation in H1 2026.
- Next-generation peptide MC4R agonist planned for IND submission in H2 2026.
- Strengthened balance sheet following 18200000 public offering.
- Sublicensing of PL9643 provides potential future milestones and royalties.
- Cash runway expected beyond March 31, 2027.
Challenges Ahead
- Continued net losses driven by R&D and operating expenses.
- Increased operating expenses compared to prior year.
- Dependence on successful IND submissions and clinical trial outcomes.
- Limited current revenue base.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...